Towards the Microbial Production of Plant-Derived Anticancer Drugs

Authors :: Sébastien Besseau
Vincent Courdavault
Sarah E. O'Connor
Nicolas Papon
Audrey Oudin
Biomolécules et biotechnologies végétales (BBV EA 2106)
Université de Tours (UT)
Max Planck Institute for Chemical Ecology
Max-Planck-Gesellschaft
Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP)
Université d'Angers (UA)
SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques (ICAT)
Université de Tours
Source :: Trends in Cancer, Trends in Cancer, Cell Press, 2020, 6 (6), pp.444-448. ⟨10.1016/j.trecan.2020.02.004⟩
Publication Year :: 2020
Abstract: Many of the plant-derived compounds used in chemotherapies are currently produced by semisynthesis, which results in limited supplies at exorbitant market prices. However, the synthetic biology era, which began ca 15 years ago, has progressively yielded encouraging advances by using engineered microbes for the practical production of cheaper plant anticancer drugs.

Full Text Access

Tools